Abstract
Replacement of the core beta-amino acid in our previously reported piperidine acetic acid and beta-phenylalanine-based Bradykinin B1 antagonists by dihydroquinoxalinone acetic acid increases the in vitro potency and metabolic stability. The most potent compounds from this series have IC(50)s<0.2 nM in a human B1 receptor functional assay. A molecular modeling study of the binding modes of key compounds, based on a B1 homology model, explains the structure-activity relationship (SAR) for these analogs.
MeSH terms
-
Acetamides / chemical synthesis*
-
Acetamides / chemistry
-
Acetic Acid / chemistry
-
Amines
-
Bradykinin B1 Receptor Antagonists*
-
Chemistry, Pharmaceutical / methods*
-
Drug Design
-
Humans
-
Inhibitory Concentration 50
-
Ligands
-
Models, Chemical
-
Molecular Conformation
-
Molecular Structure
-
Protein Binding
-
Quinoxalines / chemical synthesis*
-
Quinoxalines / pharmacology
-
Receptor, Bradykinin B1 / chemistry*
-
Structure-Activity Relationship
Substances
-
Acetamides
-
Amines
-
Bradykinin B1 Receptor Antagonists
-
Ligands
-
Quinoxalines
-
Receptor, Bradykinin B1
-
Acetic Acid